Publications:

Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.

Mabs

RJ Hansen, MJ Berna, AE Sperry, TP Beyer, VJ Wroblewski, KM Schroeder, PI Eacho

Publication Date: 2017

Variant appearance in text: PCSK9: R215A

PubMed Link: 27981884

Variant Present in the following documents:

• Main text

View BVdb publication page

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

Journal Of Lipid Research

KM Schroeder, TP Beyer, RJ Hansen, B Han, RT Pickard, VJ Wroblewski, MC Kowala, PI Eacho

Publication Date: 2015-11

Variant appearance in text: PCSK9: R215A

PubMed Link: 26392590

Variant Present in the following documents:

• Main text

View BVdb publication page

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

The Journal Of Biological Chemistry

MT Lipari, W Li, P Moran, M Kong-Beltran, T Sai, J Lai, SJ Lin, G Kolumam, J Zavala-Solorio, A Izrael-Tomasevic, D Arnott, J Wang, AS Peterson, D Kirchhofer

Publication Date: 2012-12-21

Variant appearance in text: PCSK9: R215A

PubMed Link: 23135270

Variant Present in the following documents:

• Main text

View BVdb publication page

Alternative transcript annotations: